This is reinforced by analysis of patients diagnosed with juvenile arthritis treated with the monoclonal anti-IL-6R antibody Tocilizumab; many of these individuals achieved normalized growth rates when their serum IL-6 levels normalized68. Here, IL6R is linked to juvenile idiopathic arthritis.